Lineage Cell Therapeutics (LCTX) Cost of Revenue (2011 - 2025)
Lineage Cell Therapeutics (LCTX) reported Cost of Revenue of $66000.0 for Q4 2025, down 57.14% on a YoY basis from $154000.0 in Q4 2024, and up 1220.0% quarter-over-quarter from $5000.0 in Q3 2025.
Lineage Cell Therapeutics (LCTX) Cost of Revenue (2011 - 2025) Analysis & Trends
Lineage Cell Therapeutics has reported Cost of Revenue for 15 years, with the latest figure at $66000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cost of Revenue fell 57.14% year-over-year to $66000.0; the trailing twelve-month figure through Mar 2026 stood at $110000.0 (down 59.56% YoY), and the FY2025 full-year result was $146000.0, down 56.29% from the prior year.
- Cost of Revenue for Q4 2025 stood at $66000.0, up from $5000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $985000.0 in Q3 2021, with the low at $5000.0 in Q3 2025.
- Historically, Cost of Revenue has averaged $173800.0 across 5 years, with a median of $122000.0 in 2021.
- Annual changes were most pronounced in 2021 — Cost of Revenue surged 865.69% — and 2025, when it plunged 86.84%.
- Lineage Cell Therapeutics' Cost of Revenue stood at $204000.0 in 2021, then slumped by 50.0% to $102000.0 in 2022, then jumped by 150.98% to $256000.0 in 2023, then slumped by 39.84% to $154000.0 in 2024, then sank by 57.14% to $66000.0 in 2025.
- The last three Cost of Revenue figures came in at $66000.0 (Q4 2025), $5000.0 (Q3 2025), and $39000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 66,000.00 |
| Dec 31, 2025 | 66,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | 256,000.00 |
| Dec 31, 2023 | 256,000.00 |
| Sep 30, 2023 | 169,000.00 |
| Sep 30, 2023 | 169,000.00 |